Navigation Links
HART's CMO Dr. Saverio La Francesca to moderate panel on "Regenerative Engineering and Bio-Materials" at World Stem Cell Summit Saturday, Dec. 12
Date:12/8/2015

ATLANTA and HOLLISTON, Mass., Dec. 8, 2015 /PRNewswire/ -- Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions, today announced that Executive Vice President and Chief Medical Officer Saverio La Francesca, MD will moderate and speak at the World Stem Cell Summit during a secession entitled "Regenerative Engineering and Bio-Materials" on Saturday, December 12, 2015 at 2:00 p.m. ET. The conference will be held at the Hyatt Regency in Atlanta, GA. 

HART's cell frame technology utilizes the patient's own stem cells combined with its proprietary scaffold to restore organ function in the airways and esophagus. HART recently reported significant improvements in their Gen2 product implants.

About Dr. Saverio La Francesca:
Dr. La Francesca is a cardiothoracic surgeon with over 25 years of academic, clinical surgical practice and innovative research, in the cardiovascular, thoracic transplantation, cardiac assist device and regenerative medicine fields. Previously he worked with the Dept. of Cardiovascular Surgery and Transplantation at DeBakey Heart and Vascular Center at the Houston Methodist Hospital, where he developed the current surgical and perfusion techniques for thoracic organ procurement and preservation. He was also an attending surgeon at the Department of Cardiopulmonary Transplantation at the Texas Heart Institute in Houston, Texas. Dr. La Francesca holds UNOS certifications as heart transplant surgeon and lung transplant surgeon and is a certified surgeon for the use of the HeartMate and the Jarvik 2000 left ventricular assist devices.

About World Stem Cell Summit (worldstemcellsummit.com)
The World Stem Cell Summit, produced by the Genetics Policy Institute (GPI), is the largest interdisciplinary, networking meeting of stem cell science and regenerative medicine stakeholders, uniting the diverse community. With the overarching purpose of fostering biomedical research, funding and investments targeting cures, the Summit is the single conference charting the future of this burgeoning field. Featuring more than 200 renowned international speakers and 65 hours of in-depth programming, the World Stem Cell Summit unites, educates, and harmonizes the global stem cell community.

About HART: (www.hartregen.com)
Harvard Apparatus Regenerative Technology (HART) makes bioengineered organ implants for life-threatening conditions. Our technology platform is to be used to restore function in the esophagus and the airways (trachea and bronchus). HART is completing further large-animal studies to refine our technology platform with the goal of filing an Investigational New Drug (IND) application with the U.S. Food and Drug Administration in 2016, seeking to initiate clinical trials for one of our three product candidates. Our first-generation trachea technology was used in five adult human trachea transplants approved under compassionate use exemptions, but none of our products are yet approved for marketing by a government regulatory authority.

Twitter:  Investor Relations @HART_IR_Team 
StockTwits: @HART_IR

Contact:
Catalyst Global LLC
David Collins, Tanya Kamatu
212-924-9800
hart@catalyst-ir.com

Logo - http://photos.prnewswire.com/prnh/20151110/286060LOGO

 


'/>"/>
SOURCE Harvard Apparatus Regenerative Technology, Inc.
Copyright©2015 PR Newswire.
All rights reserved


Related biology technology :

1. The EQUITY Series of Business/Medical Thrillers by Award-winning Author Rudy Mazzocchi, Continue to Climb the Charts
2. Chemical Publishing Company to Release New Title Boiler Water Treatment Principles and Practice: Charts and Notes for Field Use
3. Bayer CropScience Charts Course For Cultivating Bee Health Solutions With Opening Of Clayton Bee Care Facility
4. Princeton report charts a step-by-step path toward a nuclear weapons-free Middle East
5. Infinata's BioPharm Insight Global Editor Kim Ha to Moderate Panel at 3rd Annual U.S.-China Conference on Strategies for Mining Profits from Pharma Opportunities in China
6. Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
7. Favorable Demographics Will Drive Moderate Expansion In The US Market For Skin Replacements And Substitutes
8. Ember Therapeutics Announce Initial Positive Results From a Phase 2 Trial of BMP-7 in Patients with Moderate Osteoarthritis of the Knee
9. Moderate Drinkers Who Abstain for Even a Short Time Reduce Risk Factors for Non-alcoholic Fatty Liver Disease
10. Dominion Diagnostics to Sponsor 2013 Addiction Professional Panel Series as Thought Leadership Partner
11. Dyadic International To Speak At Advanced Biofuels Leadership Conference Panel Discussion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/18/2018)... NEW YORK (PRWEB) , ... October 18, 2018 , ... ... choosing to freeze and store their eggs. Previously reserved for women facing a cancer ... today are doing so to preserve their options. Simply put, they do not ...
(Date:10/16/2018)... ... October 16, 2018 , ... ... the first Congressional briefing on a revolutionary technology that effectively treats pain, reduces ... of Infinity Healing, testified on how technology using photobiomodulation (PBM) has been effective ...
(Date:10/11/2018)... ... 11, 2018 , ... Umbilical cord blood is now playing ... anemia, among others, and the medical industry has been moving toward the commercialization ... advice on ways to maintain the integrity and the viability of cord blood ...
(Date:10/5/2018)... (PRWEB) , ... October 04, 2018 , ... ... new brand identity and website that elevates the company’s brand identity and better ... the company offers a broader range of engineering expertise and related support services ...
Breaking Biology Technology:
(Date:10/18/2018)... ... October 18, 2018 , ... On June 11 of ... emerging field of gene-editing therapeutics to hold its collective breath. Two different research ... high frequency of p53 gene mutation. Mutations in the p53 gene have the ...
(Date:10/18/2018)... (PRWEB) , ... October 18, 2018 , ... ... to reality , Texas A&M receives USDA-APHIS deregulation approval , Writer: Kay Ledbetter, ... to deliver protein to millions of people, a project to which Dr. Keerti ...
(Date:10/17/2018)... SAN FRANCISCO (PRWEB) , ... ... ... the leading executive search firm for life sciences, diagnostics, and scientific healthcare ... taking place October 25, 2018 in South San Francisco. In conjunction with ...
Breaking Biology News(10 mins):